STS is designed to accurately identify and characterise all genomic alterations in 42 clinically relevant genes. Credit: PublicDomainPictures from Pixabay.

SOPHiA GENETICS’ Solid Tumor Solution (STS) has been granted a Conformité Européene in-vitro diagnostic (CE-IVD) mark.

This molecular diagnostic device is designed to detect solid tumours. It is based on the company’s artificial intelligence (AI) technology, which uses statistical inference, pattern recognition and machine learning to analyse genomics and radiomics data.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

STS identifies and characterises genomic alterations in 42 clinically relevant genes related to a variety of solid tumours, including lung, colorectal, skin and brain cancers.

The company aims to provide clinicians with access to therapeutic, prognostic and diagnostic databases that would enable decisions on genomic alterations related to a specific type of cancer.

“As about one in six deaths is due to cancer nowadays, it is essential to give patients an early and precise diagnosis.”

STS identifies single nucleotide variants (SNV), insertions, deletions (Indels) and gene amplifications, as well as microsatellite instability (MSI) status in six locations associated with colorectal cancer.

SOPHiA GENETICS genomics senior vice-president Gioia Althoff said: “As about one in six deaths is due to cancer nowadays, it is essential to give patients an early and precise diagnosis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The newly approved CE-IVD STS represents a major advancement in the personalisation of cancer care. It is designed to maximise diagnostic yield and guide treatment and management decisions.”

The company noted that cancer resulted in an estimated 9.6 million deaths last year, becoming the second primary cause of death worldwide.

In February last year, SOPHiA GENETICS secured a CE-IVD mark for its Myeloid Solution, a capture-based molecular diagnostic clinical application intended for detecting haematological disorders.

Myeloid Solution leverages AI to analyse circulating tumour DNA (ctDNA) in liquid samples such as blood, urine and cerebral spinal fluid.